Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 100,000 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 100,000 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $35.22, for a total value of $3,522,000.00. Following the sale, the chief executive officer now owns 27,918 shares in the company, valued at $983,271.96. The trade was a 78.18 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.08, for a total value of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total transaction of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.09, for a total value of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total transaction of $1,118,663.94.

Hims & Hers Health Trading Up 0.6 %

Shares of HIMS stock opened at $42.12 on Thursday. The company’s 50-day moving average price is $29.82 and its 200-day moving average price is $23.00. Hims & Hers Health, Inc. has a twelve month low of $8.58 and a twelve month high of $44.43. The stock has a market cap of $9.20 billion, a price-to-earnings ratio of 95.72 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.04) earnings per share. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of HIMS. Crewe Advisors LLC purchased a new stake in Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. raised its stake in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after acquiring an additional 1,413 shares during the last quarter. US Bancorp DE increased its holdings in Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after purchasing an additional 1,508 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in Hims & Hers Health in the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HIMS. Piper Sandler increased their target price on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Monday, January 6th. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their price objective for the company from $24.00 to $25.00 in a report on Friday, January 10th. Morgan Stanley started coverage on Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. BTIG Research initiated coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.